<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="55455">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02069132</url>
  </required_header>
  <id_info>
    <org_study_id>VIALE</org_study_id>
    <secondary_id>FARM9JNT9Y</secondary_id>
    <secondary_id>2012-002578-30</secondary_id>
    <nct_id>NCT02069132</nct_id>
  </id_info>
  <brief_title>Validation of International Warfarin Pharmacogenetics Consortium (IWPC) Algorithm in Elderly Patients With Comorbidity</brief_title>
  <acronym>VIALE</acronym>
  <official_title>Prospective Validation of IWPC Pharmacogenetic Algorithm for Estimating the Appropriate Initial Dose of Warfarin in Elderly People (65 or Older) With Heart Valves Prostheses or Non Valvular Atrial Fibrillation and Comorbidity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Second University of Naples</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Federico II University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Salerno</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Second University of Naples</source>
  <oversight_info>
    <authority>Italy: Ethics Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to validate the International Warfarin Pharmacogenetics
      Consortium (IWPC) algorithm in a prospective cohort of elderly people (65 years or older)
      with heart valves and/or nonvalvular atrial fibrillation (AF) and at least one comorbid
      condition, and to assess the algorithm's prognostic relevance.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Anticipated">September 2016</completion_date>
  <primary_completion_date type="Anticipated">March 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Percentage of patients whose predicted dose of warfarin is within 20% of the actual stable therapeutic dose.</measure>
    <time_frame>up to 12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>stable warfarin dosing is defined as the mean daily does required to achieve three or more consecutive International Normalized Ratio (INR) measurements within the individual's target range, at the same daily does.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients for whom the predicted dose is at least 20% higher than the actual dose (overestimation) or at least 20% lower than the actual dose (underestimation).</measure>
    <time_frame>up to 12 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of cardiovascular and cerebrovascular events</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>composite endpoint: death for any cause, hospitalization for cardiovascular and cerebrovascular events, major bleeding  or thromboembolism</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of patients with major bleeding events</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>major bleeding: (i) fatal bleeding; and/or (ii) symptomatic bleeding in a critical area or organ; and/or (iii) bleeding causing a fall in haemoglobin level of ≥2 g/dL or leading to transfusion of two or more units of blood or red cells.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of  thromboembolic event</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>thromboembolism is defined as occurrence of cerebral infarction, myocardial infarction, peripheral arterial embolism.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of cardiovascular and cerebrovascular events</measure>
    <time_frame>4 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of patient reported episodes of minor bleeding events</measure>
    <time_frame>one year</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>average maintenance dose per patient</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time to achievement of stable warfarin dosing from initiation</measure>
    <time_frame>up to 12 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time to therapeutic INR per patient</measure>
    <time_frame>up to 12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>defined as the time of first achieving INR measurement within the individual's target range, providing that INR is also within the target range at the subsequent clinic visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>percentage time in the therapeutic INR range</measure>
    <time_frame>up to 3 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>percentage time in the therapeutic INR range</measure>
    <time_frame>four weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1100</enrollment>
  <condition>Atrial Fibrillation</condition>
  <condition>Thrombus Due to Heart Valve Prosthesis</condition>
  <arm_group>
    <arm_group_label>Warfarin in elderly with comorbidity</arm_group_label>
    <description>Patients  65 years or older,  candidate for therapy with warfarin for non valvular atrial fibrillation or heart valve replacement</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Warfarin</intervention_name>
    <description>warfarin treatment will be determined by treating physicians according to in-hospital guidelines, blindly to genotype assessment.</description>
    <arm_group_label>Warfarin in elderly with comorbidity</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Whole blood
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        prospective cohort of elderly people (≥65 years) with nonvalvular atrial fibrillation
        and/or heart valve replacement, with at least one comorbid condition, presenting for
        warfarin therapy
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 65 years

          -  Patients who initiate warfarin because of non valvular atrial fibrillation or heart
             valve replacement

          -  At least one comorbid condition

          -  At least two other drugs regularly assumed over and above warfarin

        Exclusion Criteria:

          -  Presence of systemic coagulopathies

          -  Presence of malignancies needing chemotherapy

          -  Inability or refusal to give informed consent
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ciro Gallo, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Second University of Naples</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Amelia Filippelli, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Salerno</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marisa De Feo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Second University of Naples</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nicola Ferrara, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Federico II University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ciro Gallo, MD</last_name>
    <phone>+39 0815666021</phone>
    <email>ciro.gallo@unina2.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Simona Signoriello, Ph.D.</last_name>
    <phone>+39 0815666021</phone>
    <email>simona.signoriello@unina2.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Second University of Naples</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Naples Federico II</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Salerno</name>
      <address>
        <city>Salerno</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 20, 2014</lastchanged_date>
  <firstreceived_date>February 20, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Second University of Naples</investigator_affiliation>
    <investigator_full_name>Ciro Gallo</investigator_full_name>
    <investigator_title>Professor of Medical Statistics</investigator_title>
  </responsible_party>
  <keyword>Warfarin</keyword>
  <keyword>International Warfarin Pharmacogenetics Consortium algorithm</keyword>
  <keyword>Atrial Fibrillation</keyword>
  <keyword>Heart Valve Prosthesis Implantation</keyword>
  <keyword>elderly</keyword>
  <keyword>comorbidity</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Thrombosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Warfarin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
